Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity
Dyslipidemias, Obesity
About this trial
This is an interventional prevention trial for Dyslipidemias
Eligibility Criteria
Inclusion Criteria: LDL-C ≥ 130 mg/dL Waist circumference ≥ 88 cm for women, ≥ 102 cm for men Aged 40 to 70 years Exclusion Criteria: Renal disease Liver disease Diabetes Heart disease Stroke Cancer Eating disorders Thyroid disease Gut-associated pathologies Autoimmune diseases Chronic inflammatory diseases Scleroderma Gallbladder disease Blood clotting disorders Intravenous drug use Self-reported pre-menopausal status Fasting plasma/serum triglycerides >500 mg/dL Fasting plasma/serum glucose >126 mg/d Weight changes >10% over last 4 weeks Oral antibiotics use up to 1 month prior to and during study Allergy or intolerance to milk products Taking lipid-lowering medications (e.g., statins, fibrates) Taking anti-inflammatory medications (e.g., corticosteroids) Taking medications which primarily affect blood clotting (e.g., warfarin).
Sites / Locations
- University of ConnecticutRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
MPL-rich dairy powder
Control dairy powder
Daily consumption of 50 g of dairy powder containing 6.5 g MPL for 8 weeks.
Daily consumption of 50 g of dairy powder containing <0.1 g MPL for 8 weeks